Table 2. Fractions of tumor-reactive lymphocytes in large-scale expanded TIL from melanoma-invaded lymph nodes of 47 patients treated by TIL.
Patients | % IFN-γ-positive lymphocytesb | Relapse-free survivalc | |
E1a | E2 | ||
M88* | ND | 0.4 | + |
M110 | 0 | 0 | −(7) |
M113 | 10.3 | 0.8 | −(6.5) |
M117 | ND | 2.5 | + |
M125 | 0 | 2.4 | −(3) |
M131 | 0 | 0 | −(5) |
M132 | 0 | 0 | −(2) |
M134 | 0.7 | 0 | + |
M140 | 0 | 0 | + |
M153 | 0 | 0 | −(3) |
M154* | 7.2 | 13.8 | −(156) |
M158 | 0 | 0 | −(5) |
M164 | 0 | 0 | −(26) |
M167 | 0.7 | 1.8 | −(4) |
M170* | 1.2 | ND | + |
M171 | 0 | 0 | −(3) |
M177* | 1.1 | 2.2 | + |
M182 | 0 | 0.7 | + |
M187 | 2.9 | 0.4 | + |
M193 | 3.5 | 4 | −(4) |
M196* | 1 | 0 | −(6) |
M197* | 2.9 | 0 | + |
M199 | 2.7 | 2.4 | −(2) |
M200 | 1 | 0.4 | −(7) |
M204 | 0 | 3.4 | −(3) |
M212 | 0.4 | 1 | −(8) |
M218* | 9 | 11.3 | + |
M234* | 4.9 | 2.3 | −(26) |
M241* | 27.7 | 9.1 | −(13) |
M245* | 19.7 | 11.3 | −(8) |
M252* | 1.4 | ND | −(2) |
M254* | ND | 2.2 | + |
M263* | 2.56 | 1.49 | −(14) |
M275* | 12.2 | 13 | −(8.5) |
M278* | 21.5 | 11.6 | + |
M284* | 2 | 4.7 | + |
M288* | 0 | 1.5 | + |
M301* | 13.2 | 14.7 | −(6) |
M305* | 18.75 | 19.8 | + |
M314* | 0.5 | 0.2 | −(3.5) |
M329* | 3.4 | 4.2 | −(27) |
M379* | 1.2 | 1.3 | −(4) |
M386* | 1.1 | 0.9 | + |
M415* | 5.8 | 2.2 | + |
M417* | 0.56 | 0.89 | + |
M424* | ND | 8 | + |
M428* | 6.6 | 6.9 | + |
Melanoma patients bearing only one metastatic lymph node (early stage III patients).
E1 and E2 were TIL populations obtained and reinjected to the patient from respectively the first and the second ex-vivo expansions.
Percentages of IFN-γ secreting TIL were estimated by intracellular labeling. TIL were stimulated 6 h by autologous melanoma cells in presence of brefeldin A. Then, cells were fixed, permeabilized, stained for cytokine production and analyzed on a FACScalibur.
Relapse-free survival of patients (−): patients who relapsed,(months); (+): patients who did not relapse.